vs
BioNTech SE（BNTX）与Cellectis S.A.（CLLS）财务数据对比。点击上方公司名可切换其他公司
BioNTech SE的季度营收约是Cellectis S.A.的159.8倍（$1.5B vs $9.5M）。BioNTech SE净利率更高（-1.9% vs -265.9%，领先264.0%）
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
BNTX vs CLLS — 直观对比
营收规模更大
BNTX
是对方的159.8倍
$9.5M
净利率更高
BNTX
高出264.0%
-265.9%
损益表 — Q3 2025 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $9.5M |
| 净利润 | $-28.7M | $-25.3M |
| 毛利率 | — | — |
| 营业利润率 | -3.1% | -181.1% |
| 净利率 | -1.9% | -265.9% |
| 营收同比 | — | 375.0% |
| 净利润同比 | — | -51.9% |
| 每股收益（稀释后） | — | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNTXCLLS
| Q3 25 | $1.5B | — | ||
| Q2 25 | $260.8M | — | ||
| Q1 25 | $182.8M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $128.7M | $9.5M | ||
| Q1 24 | $187.6M | — | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | — | $2.0M |
净利润BNTXCLLS
| Q3 25 | $-28.7M | — | ||
| Q2 25 | $-386.6M | — | ||
| Q1 25 | $-415.8M | — | ||
| Q3 24 | $198.1M | — | ||
| Q2 24 | — | $-25.3M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | — | $-16.6M |
毛利率BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 97.3% |
营业利润率BNTXCLLS
| Q3 25 | -3.1% | — | ||
| Q2 25 | -192.1% | — | ||
| Q1 25 | -292.2% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | -750.7% | -181.1% | ||
| Q1 24 | -270.4% | — | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | — | -1180.5% |
净利率BNTXCLLS
| Q3 25 | -1.9% | — | ||
| Q2 25 | -148.2% | — | ||
| Q1 25 | -227.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | — | -265.9% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | — | -831.6% |
每股收益（稀释后）BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.28 | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | — | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $149.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $148.6M |
| 总资产 | — | $407.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $149.0M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $84.4M |
股东权益BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $148.6M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | — | $96.6M |
总资产BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $407.1M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | — | $227.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $28.9M |
| 自由现金流经营现金流 - 资本支出 | — | $27.6M |
| 自由现金流率自由现金流/营收 | — | 290.5% |
| 资本支出强度资本支出/营收 | — | 13.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $28.9M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.4M |
自由现金流BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $27.6M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.9M |
自由现金流率BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 290.5% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -2391.4% |
资本支出强度BNTXCLLS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 13.2% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 24.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
